P-021. Transient deterioration of glucose metabolism during GH treatment of GH deficient adults

A. I. Pincelli, A. Brunani, M. Scacchi, L. Pasqualinotto, A. Tibaldi, A. Dubini, R. Viarengo, L. Papagni, F. Cavagnini

Research output: Contribution to journalArticle

Abstract

When administered to normal man, GH has been shown to cause hyperglycaemia and insulin resistance, by increasing hepatic glucose production and by decreasing glucose uptake in insulin-dependent tissues. Aim of the study was to investigate the effect of chronic administration of GH on glucose tolerance and insulin; sensitivity in GH deficient adults in relation to their visceral fat. Study: 10 GH deficient adult patients (age 28-49 yrs, BMI 26±1.9 kg/m 2) were studied at baseline, and after 6 and 12 months of GH therapy (Genotropin, Pharmacia) at a dose of 0.125 U/kg/week for the first month and 0.25 U/kg/week thereafter, in a double blind placebo-controlled study. Glucose tolerance was evaluated by 75 g oral glucose load and insulin resistance by euglycaemic-hyperinsulinemic clamp, with an insulin infusion rate of 1 mU/kg/min. The visceral fat was determined by computed tomography. Results: In the OGTT studies, glucose tolerance, normal at baseline, worsened slightly at 6 months of GH therapy (glucose AUC 31365±2067.6 vs 26630±2214.0mg/dl/min, p3, p

Original languageEnglish
Pages (from-to)43-44
Number of pages2
JournalEndocrinology and Metabolism, Supplement
Volume4
Issue numberA
Publication statusPublished - 1997

Fingerprint

Glucose
Intra-Abdominal Fat
Insulin
Therapeutics
Insulin Resistance
Glucose Clamp Technique
Human Growth Hormone
Glucose Tolerance Test
Hyperglycemia
Area Under Curve
Tomography
Placebos
Liver

ASJC Scopus subject areas

  • Endocrinology

Cite this

P-021. Transient deterioration of glucose metabolism during GH treatment of GH deficient adults. / Pincelli, A. I.; Brunani, A.; Scacchi, M.; Pasqualinotto, L.; Tibaldi, A.; Dubini, A.; Viarengo, R.; Papagni, L.; Cavagnini, F.

In: Endocrinology and Metabolism, Supplement, Vol. 4, No. A, 1997, p. 43-44.

Research output: Contribution to journalArticle

Pincelli, AI, Brunani, A, Scacchi, M, Pasqualinotto, L, Tibaldi, A, Dubini, A, Viarengo, R, Papagni, L & Cavagnini, F 1997, 'P-021. Transient deterioration of glucose metabolism during GH treatment of GH deficient adults', Endocrinology and Metabolism, Supplement, vol. 4, no. A, pp. 43-44.
Pincelli, A. I. ; Brunani, A. ; Scacchi, M. ; Pasqualinotto, L. ; Tibaldi, A. ; Dubini, A. ; Viarengo, R. ; Papagni, L. ; Cavagnini, F. / P-021. Transient deterioration of glucose metabolism during GH treatment of GH deficient adults. In: Endocrinology and Metabolism, Supplement. 1997 ; Vol. 4, No. A. pp. 43-44.
@article{599a599b7d9c4cfd84159c48a557b629,
title = "P-021. Transient deterioration of glucose metabolism during GH treatment of GH deficient adults",
abstract = "When administered to normal man, GH has been shown to cause hyperglycaemia and insulin resistance, by increasing hepatic glucose production and by decreasing glucose uptake in insulin-dependent tissues. Aim of the study was to investigate the effect of chronic administration of GH on glucose tolerance and insulin; sensitivity in GH deficient adults in relation to their visceral fat. Study: 10 GH deficient adult patients (age 28-49 yrs, BMI 26±1.9 kg/m 2) were studied at baseline, and after 6 and 12 months of GH therapy (Genotropin, Pharmacia) at a dose of 0.125 U/kg/week for the first month and 0.25 U/kg/week thereafter, in a double blind placebo-controlled study. Glucose tolerance was evaluated by 75 g oral glucose load and insulin resistance by euglycaemic-hyperinsulinemic clamp, with an insulin infusion rate of 1 mU/kg/min. The visceral fat was determined by computed tomography. Results: In the OGTT studies, glucose tolerance, normal at baseline, worsened slightly at 6 months of GH therapy (glucose AUC 31365±2067.6 vs 26630±2214.0mg/dl/min, p3, p",
author = "Pincelli, {A. I.} and A. Brunani and M. Scacchi and L. Pasqualinotto and A. Tibaldi and A. Dubini and R. Viarengo and L. Papagni and F. Cavagnini",
year = "1997",
language = "English",
volume = "4",
pages = "43--44",
journal = "Endocrinology and Metabolism, Supplement",
issn = "1074-939X",
publisher = "Bailliere Tindall Ltd",
number = "A",

}

TY - JOUR

T1 - P-021. Transient deterioration of glucose metabolism during GH treatment of GH deficient adults

AU - Pincelli, A. I.

AU - Brunani, A.

AU - Scacchi, M.

AU - Pasqualinotto, L.

AU - Tibaldi, A.

AU - Dubini, A.

AU - Viarengo, R.

AU - Papagni, L.

AU - Cavagnini, F.

PY - 1997

Y1 - 1997

N2 - When administered to normal man, GH has been shown to cause hyperglycaemia and insulin resistance, by increasing hepatic glucose production and by decreasing glucose uptake in insulin-dependent tissues. Aim of the study was to investigate the effect of chronic administration of GH on glucose tolerance and insulin; sensitivity in GH deficient adults in relation to their visceral fat. Study: 10 GH deficient adult patients (age 28-49 yrs, BMI 26±1.9 kg/m 2) were studied at baseline, and after 6 and 12 months of GH therapy (Genotropin, Pharmacia) at a dose of 0.125 U/kg/week for the first month and 0.25 U/kg/week thereafter, in a double blind placebo-controlled study. Glucose tolerance was evaluated by 75 g oral glucose load and insulin resistance by euglycaemic-hyperinsulinemic clamp, with an insulin infusion rate of 1 mU/kg/min. The visceral fat was determined by computed tomography. Results: In the OGTT studies, glucose tolerance, normal at baseline, worsened slightly at 6 months of GH therapy (glucose AUC 31365±2067.6 vs 26630±2214.0mg/dl/min, p3, p

AB - When administered to normal man, GH has been shown to cause hyperglycaemia and insulin resistance, by increasing hepatic glucose production and by decreasing glucose uptake in insulin-dependent tissues. Aim of the study was to investigate the effect of chronic administration of GH on glucose tolerance and insulin; sensitivity in GH deficient adults in relation to their visceral fat. Study: 10 GH deficient adult patients (age 28-49 yrs, BMI 26±1.9 kg/m 2) were studied at baseline, and after 6 and 12 months of GH therapy (Genotropin, Pharmacia) at a dose of 0.125 U/kg/week for the first month and 0.25 U/kg/week thereafter, in a double blind placebo-controlled study. Glucose tolerance was evaluated by 75 g oral glucose load and insulin resistance by euglycaemic-hyperinsulinemic clamp, with an insulin infusion rate of 1 mU/kg/min. The visceral fat was determined by computed tomography. Results: In the OGTT studies, glucose tolerance, normal at baseline, worsened slightly at 6 months of GH therapy (glucose AUC 31365±2067.6 vs 26630±2214.0mg/dl/min, p3, p

UR - http://www.scopus.com/inward/record.url?scp=33747651599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747651599&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33747651599

VL - 4

SP - 43

EP - 44

JO - Endocrinology and Metabolism, Supplement

JF - Endocrinology and Metabolism, Supplement

SN - 1074-939X

IS - A

ER -